Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4798922 | 1.00 | EPHX2 (0.56) | EPHX2MTNR1AMTNR1BSIGMAR1SLC6A2 | |
| Fumaric Acid SCHEMBL4803469 | 0.87 | EPHX2 (0.55) | EPHX2MTNR1AMTNR1BSIGMAR1MAPK1 | |
| Fumaric Acid SCHEMBL4803477 | 0.87 | EPHX2 (0.55) | EPHX2MTNR1AMTNR1BSIGMAR1MAPK1 | |
| Maleic Acid SCHEMBL4803444 | 0.87 | EPHX2 (0.55) | EPHX2MTNR1AMTNR1BSIGMAR1MAPK1 | |
| SCHEMBL11636650 | 0.82 | EPHX2 (0.43) | EPHX2MTNR1AMTNR1BSIGMAR1DRD2 | |
| SCHEMBL8562856 | 0.79 | EPHX2 (0.65) | EPHX2MTNR1AMTNR1BMAPK1MEN1 | |
| SCHEMBL8562865 | 0.79 | EPHX2 (0.65) | EPHX2MTNR1AMTNR1BMAPK1MEN1 | |
| SCHEMBL8562858 | 0.79 | EPHX2 (0.65) | EPHX2MTNR1AMTNR1BMAPK1MEN1 | |
| SCHEMBL4830429 | 0.78 | EPHX2 (0.68) | EPHX2MTNR1AMTNR1BMAPK1 | |
| SCHEMBL8886779 | 0.78 | SIGMAR1 (0.52) | EPHX2MTNR1AMTNR1BSIGMAR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE40278-E1 | Heterocyclic amines having central nervous system activity | PHARMACIA & UPJOHN COMPANY (US) | 2008-04-29 | — | — | US | disclosed |
| US-RE40278-E1 | Heterocyclic amines having central nervous system activity | PHARMACIA & UPJOHN COMPANY (US) | 2008-04-29 | — | — | US | disclosed |
| US-RE40278-E1 | Heterocyclic amines having central nervous system activity | PHARMACIA & UPJOHN COMPANY (US) | 2008-04-29 | — | — | US | disclosed |
| US-7074927-B2 | Heterocyclic amines having central nervous system activity | PHARMACIA & UPJOHN COMPANY (US) | 2006-07-11 | — | — | US | disclosed |
| EP-1017391-B1 | SUSTAINED RELEASE TABLET FORMULATION TO TREAT PARKINSON DISEASE | PHARMACIA & UPJOHN CO LLC (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20050107378-A1 | Heterocyclic amines having central nervous system activity | ROMERO ARTHUR G (US) | 2005-05-19 | — | — | US | disclosed |
| US-RE38452-E1 | SUITABLE FOR TREATING ANXIOLYTIC DISORDER, SCHIZOPHRENIA, PARKINSON'S DISEASE, ANXIETY | PHARMACIA & UPJOHN COMPANY | 2004-03-02 | — | — | US | disclosed |
| US-20020187981-A1 | Heterocyclic amines having central nervous system activity | ROMERO ARTHUR GLENN (US) | 2002-12-12 | — | — | US | disclosed |
| US-20010053386-A1 | (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one maleate | PHARMACIA & UPJOHN COMPANY | 2001-12-20 | — | — | US | disclosed |
| US-20010009916-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | ROMERO ARTHUR G (US) | 2001-07-26 | — | — | US | disclosed |
| US-6197339-B1 | DIHYDRO-5-METHYLAMINO-4H-IMIDAZO(4,5-IJ)QUINOLINE-2(1H)ONE BUTENEDIOATE WITH STARCHES AND HYDROXYPROPYL CELLULOSE | PHARMACIA & UPJOHN COMPANY | 2001-03-06 | — | — | US | disclosed |
| EP-1017391-A2 | SUSTAINED RELEASE TABLET FORMULATION TO TREAT PARKINSON DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-12 | — | — | EP | disclosed |
| CN-1043574-C | Heterocyclic amines having central nervous system activity | UPJOHN CO (US) | 1999-06-09 | — | — | CN | disclosed |
| WO-1999016442-A2 | SUSTAINED RELEASE TABLET FORMULATION TO TREAT PARKINSON DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 1999-04-08 | — | — | WO | disclosed |
| EP-0724584-B1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | UPJOHN CO (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5652245-A | Heterocyclic amines having central nervous system activity | PHARMACIA & UPJOHN COMPANY (US) | 1997-07-29 | — | — | US | disclosed |
| EP-0724584-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 1996-08-07 | — | — | EP | disclosed |
| CN-1128030-A | Heterocyclic amines having central nervous system activity | UPJOHN CO (US) | 1996-07-31 | — | — | CN | disclosed |
| WO-1995004056-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | THE UPJOHN COMPANY (US) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009916-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | CNR1, CNR2, OPRD1 | EPHX2 3642/4885MTNR1A 64/4885MTNR1B 91/4885 |
| US-20020187981-A1 | Heterocyclic amines having central nervous system activity | CNR1, CNR2, OPRD1 | EPHX2 3640/4885MTNR1A 62/4885MTNR1B 91/4885 |
| US-20050107378-A1 | Heterocyclic amines having central nervous system activity | CNR1, CNR2, NPY2R | EPHX2 3891/4885MTNR1A 77/4885MTNR1B 109/4885 |
| US-20010053386-A1 | (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one maleate | MT-ND4, SNCA, PARK7 | EPHX2 3473/4885MTNR1A 103/4885MTNR1B 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.